Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

This trial will study a type of breast cancer defined by the expression of hormone receptor in the cancer cells (HR+). Patients will be treated with ribociclib, a cyclin-dependent kinase inhibitor, and camizestrant, a selective estrogen receptor degrader (SERD) and complete ER antagonist. The main purpose of the Study is to analyze the efficacy (to find out how effective a treatment is) of ribociclib in combination with camizestrant in patients with advanced HR+ breast cancer who have received endocrine therapy (ET) in early breast cancer setting for at least 5 years, of which at least 2 years

Trial Details

NCT ID
NCT07195227
Phase
PHASE2
Sponsor
MedSIR
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • Camizestrant
  • Ribociclib
Locations (sample)
  • Dessau, Germany|51.83864,12.24555
  • Alicante, Spain|38.34517,-0.48149
  • Barcelona, Spain|41.38879,2.15899
  • Barcelona, Spain|41.38879,2.15899
  • Girona, Spain|41.98311,2.82493

Key Eligibility Criteria

  • Patient must be capable of understanding the purpose of the Study and have signed the written informed consent form (ICF) prior to beginning specif…
  • Female or male patients ≥ 18 years of age at the time of signing ICF.
  • Pre- or peri-menopausal women or men. are eligible if treated with a Luteinizing hormone-releasing hormone (LHRH) analogue. Treatment with a LHRH i…
  • Post-menopausal women, defined by any of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →